Zobrazeno 1 - 10
of 27
pro vyhledávání: '"D R Compton"'
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 92
The development of novel drug candidates involves the thorough evaluation of potential efficacy and safety. To facilitate the safety assessment in light of global increases in prescription drug misuse/abuse, health authorities have developed guidance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57320509b74cd20245b4beb683f31197
https://pubmed.ncbi.nlm.nih.gov/29199066
https://pubmed.ncbi.nlm.nih.gov/29199066
Autor:
Thomas J. Hudzik, D R Compton
This chapter describes the regulatory impetus for potential consideration, with respect to abuse liability assessment, of certain pharmaceutical classes during the drug development process and the associated neuronal systems of potential concern. A h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b1490fea0ec654840c07c9bf6c8d059
https://doi.org/10.1016/b978-0-12-420172-9.00002-3
https://doi.org/10.1016/b978-0-12-420172-9.00002-3
Autor:
Anne M. Zimmer, Andreas Zimmer, Raj K. Razdan, Jens A. Wagner, Billy R. Martin, Nancy E. Buckley, George Kunos, Tom I. Bonner, Zoltán Járai, Károly Varga, Kristy D. Lake, D R Compton, Eva Mezey
Publikováno v:
Proceedings of the National Academy of Sciences. 96:14136-14141
Cannabinoids, including the endogenous ligand arachidonyl ethanolamide (anandamide), elicit not only neurobehavioral but also cardiovascular effects. Two cannabinoid receptors, CB1 and CB2, have been cloned, and studies with the selective CB1 recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7194453a4598c35a33ba9b07e60433e
https://doi.org/10.1073/pnas.96.24.14136
https://doi.org/10.1073/pnas.96.24.14136
Autor:
Gilbert Marciniak, Ali R. Banijamali, F.L. Friend, Sonyuan Lin, Billy R. Martin, Avgui Charalambous, D R Compton, Alexandros Makriyannis
Publikováno v:
Pharmacology Biochemistry and Behavior. 40:509-512
(-)-5'-Bromo-delta 8-THC, (-)-5'-trifluoromethyl-delta 8-THC, (-)-5'-iodo-delta 8-THC, (-)-5'-fluoro-delta 8-THC, (-)-11-fluoro-delta 8-THC and (-)-2-iodo-delta 8-THC were synthesized and evaluated in male ICR mice for their effects on sedation, temp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca3554be100772afa214bb3492f237b2
https://doi.org/10.1016/0091-3057(91)90355-6
https://doi.org/10.1016/0091-3057(91)90355-6
Autor:
Raphael Mechoulam, P. J. Little, Billy R. Martin, W. R. Prescott, S. J. Ward, L S Melvin, M R Johnson, Brian F. Thomas, D R Compton, Raj K. Razdan
Publikováno v:
Pharmacology Biochemistry and Behavior. 40:471-478
Numerous cannabinoids have been synthesized that are extremely potent in all of the behavioral assays conducted in our laboratory. An important feature in increasing potency has been the substitution of a dimethylheptyl (DMH) side chain for the penty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0021182269e7c4d0f015744581895baa
https://doi.org/10.1016/0091-3057(91)90349-7
https://doi.org/10.1016/0091-3057(91)90349-7
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 284(3)
Anandamide is the newly discovered endogenous cannabinoid ligand that binds to brain cannabinoid receptors and shares most, but not all, of the pharmacological properties of delta 9-THC. Therefore, this study was undertaken to determine whether its i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5117ffdc740ae4491bf6a9a205c09576
https://pubmed.ncbi.nlm.nih.gov/9495885
https://pubmed.ncbi.nlm.nih.gov/9495885
Autor:
D R, Compton, B R, Martin
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 283(3)
Anandamide is an putative endogenous cannabinoid ligand that produces pharmacological effects similar to those of Delta9-tetrahydrocannabinol, the principle psychoactive constituent in marijuana. There is considerable evidence that the enzyme inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e8359224bea7486a267a0634cda8d1f5
https://pubmed.ncbi.nlm.nih.gov/9399986
https://pubmed.ncbi.nlm.nih.gov/9399986
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 281(3)
Previous studies indicate that the CB1 cannabinoid receptor antagonist, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-met hyl-1H-pyrazole-3-carboxamide HCl (SR141716A), inhibits the anandamide- and delta9-tetrahydrocannabinol- (THC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5f0b34a65f604b3985468a2b364de41
https://pubmed.ncbi.nlm.nih.gov/9190833
https://pubmed.ncbi.nlm.nih.gov/9190833
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 278(3)
Two cannabinoid receptors have been identified to date; one is located predominantly in the central nervous system (CB1), whereas the other is located exclusively in the periphery (CB2). The purposes of this study were to explore further the binding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::78052a08e6153760e4560caa81984768
https://pubmed.ncbi.nlm.nih.gov/8819477
https://pubmed.ncbi.nlm.nih.gov/8819477
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 277(2)
SR141716A has been described as a cannabinoid receptor antagonist. This study was conducted to determine whether SR141716A was capable of antagonizing the pharmacological effects of the prototypical cannabinoid agonist delta 9-THC. The AD50 (+/- 95%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0fc642cc4bded8ee8939ce5e38fb0ff9
https://pubmed.ncbi.nlm.nih.gov/8627535
https://pubmed.ncbi.nlm.nih.gov/8627535